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It is well known that adenine-based purines exert multiple effects on pain transmission. Recently, we
have demonstrated that guanine-based purines may produce some antinociceptive effects against che-
mical and thermal pain in mice. The present study was designed to investigate the antinociceptive effects
of intrathecal (i.t.) administration of inosine or guanine in mice. Additionally, investigation into the
mechanisms of action of these purines, their general toxicity and measurements of CSF purine levels
were performed. Animals received an i.t. injection of vehicle (30 mN NaOH), inosine or guanine (up to
600 nmol) and submitted to several pain models and behavioural paradigms. Guanine and inosine
produced dose-dependent antinociceptive effects in the tail-ﬂick, hot-plate, intraplantar (i.pl.) glutamate,
i.pl. capsaicin and acetic acid pain models. Additionally, i.t. inosine inhibited the biting behaviour induced
by spinal injection of capsaicin and i.t. guanine reduced the biting behaviour induced by spinal injection
of glutamate or AMPA. Intrathecal administration of inosine (200 nmol) induced an approximately 115-
fold increase on CSF inosine levels. This study provides new evidence on the mechanism of action of
extracellular guanine and inosine presenting antinociceptive effects following spinal administration.
These effects seem to be related, at least partially, to the modulation of A1 adenosine receptors.
& 2015 Elsevier B.V. All rights reserved.1. Introduction
The purinergic system involves adenosine and ATP as major
endogenous effectors, acting on P1 and P2 receptors, respectively
(Burnstock, 2007). It is well known that the purinergic system,
including ATP and its metabolite adenosine, plays a relevantdenosine receptor type 2A; A3, ad
zolepropionic acid; AOPCP, ɑ,β-me
l sulfoxide; DPCPX, 8-cyclopentyl-1
hosphate; GMP, guanosine monop
omatography; IMP, inosine monop
enosine A3 receptor antagonist; NM
eptor type 2 2/3; PNP, purine nuc
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ino)ethyl)phenol, a selective aden
-Anexo, 90035-003 Porto Alegre, Rphysiological role in the control of pain at the peripheral and
central nervous system (CNS) (Sawynok and Liu, 2003). ATP can
stimulate sensory nerve endings causing pain and, by acting via
P2 3 and P2 2/3 receptors, is associated with the initiation of
acute, inﬂammatory, neuropathic, and visceral pain (Burnstock,
2007). Adenosine regulates pain transmission in the spinal cordenosine receptor type 3; ADP, adenosine diphosphate; AMP, adenosine monopho-
thyleneadenosine 5′-diphosphate; ATP, adenosine triphosphate; CNS, central ner-
,3-dipropylxanthine; SCH58261, 5-amino-2-(2-furyl)-7-phenylethyl-pyra-zolo-(4,3-
hosphate; GTP, guanosine triphosphate; HGPRT, hypoxanthine-guanine phosphor-
hosphate; i.t., intrathecal; MPE, maximum possible effect; MRS-3777, 2-phenoxy-6-
DA, N-methyl-D-aspartate; P1, purine receptor type 1; P2, purine receptor type 2;
leoside phosphorylase; 8-PT, 8-phenyltheophylline, a nonselective adenosine A1
TRPV1, transient receptor potential channel type 1; ZM241385, 4-(2-((7-amino-2-
osine A2A receptor antagonist
S, Brazil.
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paradigms (McGaraughty and Jarvis, 2005).
Adenosine is converted to inosine by the action of the enzyme
adenosine deaminase (Schmidt et al., 2007). Inosine is an en-
dogenous purine nucleoside well known for its anti-inﬂammatory
effects (Haskó et al., 2000, 2004). Inosine inhibits the release of
proinﬂammatory cytokines in activated macrophages, protects
against lung tissue damage and skeletal muscle reperfusion injury
in mice, is neuroprotective and exerts powerful anti-inﬂammatory
effects against several in vivo models of inﬂammation and shock
(Gomez and Sitkovsky, 2003). Although several studies have ex-
tensively reported the effects of adenosine against pain (Sawynok
and Liu, 2003), only modest evidence has been demonstrated
about the antinociceptive effect of inosine (Nascimento et al., 2010,
2014).
Although ATP and adenosine are usually considered the main
effectors of the purinergic system (Burnstock, 2007), extracellular
guanine-based purines exert biological effects unrelated to direct
G-proteins modulation, including the modulation of glutamate
activity (Souza and Ramirez, 1991), trophic effects on neural cells
(Ciccarelli et al., 2001), neuroprotective effects (Frizzo et al., 2002)
and behavioural effects (Paniz et al., 2014). Additionally, guanine-
based purines prevent glutamate-induced seizures and neuro-
toxicity (Schmidt and Souza, 2010), and are anxiolytic/amnesic in
rodents (Vinadé et al., 2003). Several of these behavioural effects
seem to be related to conversion to guanosine (Soares et al., 2004).
Previous studies demonstrated that intracerebroventricular, spinal
or systemic administration of guanosine produces antinociceptive
effects in several chemical and thermal pain models in rodents
(Schmidt et al., 2010a, 2010b). Additionally, we have shown that
guanosine produces signiﬁcant inhibition of glutamate- or non-
NMDA glutamate receptor agonist-induced biting behaviour
(Schmidt et al., 2009c). Importantly, most of these effects seem to
be related, at least partially, to a guanosine-induced modulation of
the glutamatergic pathways.
Notably, some data have indicated that extracellular guanine
might exert some biological effects (Jiang et al., 2008). Since sys-
temic administration of guanosine increases both guanosine and
guanine levels at the CNS (Jiang et al., 2008) and at other tissues
(Giuliani et al., 2012), and considering that some guanine-based
purines effects may be regulated by their conversion to guanine, a
role for guanine in the antinociceptive effects of guanine-based
purines can not be excluded.
The present study was designed to investigate the antinociceptive
effects of intrathecal (i.t.) administration of guanine (following the
metabolism of guanosine) or inosine (following the metabolism of
adenosine) in mice. Attempts have been made to further investigate
some of the possible mechanisms that underlie the antinociceptive
properties of those purines, especially the adenosinergic and gluta-
matergic mechanisms. Moreover, we assessed potential toxicity in-
duced by guanine or inosine following spinal administration.2. Material and methods
2.1. Animals
Male adult Swiss albino mice (3–4 months of age, 30–40 g)
were kept on a 12 h light/dark cycle (light on at 7:00 am) at
temperature of 2271 °C, housed in plastic cages with tap water
and commercial food ad libitum. In all nociceptive behavioural
experiments, the animals were acclimatized to the laboratory for
at least 60 min before testing. The ethical guidelines for in-
vestigations of experimental pain in conscious animals (Zimmer-
mann, 1983) and ARRIVE guidelines (Kilkenny et al., 2010) were
followed throughout. The number of animals and intensities ofnoxious stimuli used were the minimum necessary to demonstrate
the consistent effects of the drug treatments.
2.2. Drugs
Guanine, inosine, adenosine, caffeine, L-glutamic acid hydrochloride
(glutamate), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA), kainic acid (kainate), N-methyl-D-aspartic acid (NMDA), (7)-
1-aminocyclopentane-trans-1,3-dicarboxylic acid (trans-ACPD), and
capsaicin were purchased from Sigma Chemicals (St Louis, MO, USA).
SCH58261 (5-amino-2-(2-furyl)-7-phenylethyl-pyrazolo-(4,3-e)-1,2,4-
triazolo(1,5c)pyrimidine) and DPCPX (8-cyclopentyl-1,3-dipro-
pylxanthine) were purchased from Tocris (Northpoint, UK). Sodium
thiopental and morphine sulphate were obtained from Cristália (SP,
Brazil). Guanine and inosine were dissolved in 30mN NaOH. The
amount of NaOH caused no detectable effect. Capsaicin was diluted in
5% DMSO (dimethyl sulfoxide). DPCPX and SCH58261 were diluted in
10% DMSO. All other solutions were dissolved in saline (NaCl 0.9%) and
buffered with 0.1 N NaOH or 0.1 N HCl to pH 7.4 when necessary.
2.3. Drugs administration and intrathecal injection
Experiments were performed according to Schmidt et al. (2009b):
20 min before the experiment, animals were placed individually in
acrylic boxes, which served as observation chambers. Spinal injec-
tions were given to animals using the method described by Hylden
and Wilcox (1986). Importantly, the spinal route was chosen in order
to investigate the mechanism of action of guanosine and inosine
directly at a central site. All i.t. injections were performed with dis-
posable 30 gauge ½ inch needles mated to a 10-μl syringe. Mice were
held ﬁrmly by the pelvic girdle, while the needle was introduced at
an angle of about 20° above the vertebral column. The needle was
inserted between the L5 and L6 spinous processes and moved care-
fully forward to the intervertebral space as the angle of the syringe
was decreased to about 10°. The tip of the needle was inserted ap-
proximately 0.5 cm within the vertebral column. Animals were
treated with an i.t. injection (8 μl) of vehicle (30 mN NaOH), guanine
or inosine (200–600 nmol) 5 min before behavioural evaluation.
Morphine (10 nmol, i.t.) was used as a positive control in some ex-
periments. The doses and time of drug administration were selected
on the basis of previous ﬁndings (Schmidt et al., 2000, 2009a,b; Lara
et al., 2001; Vinadé et al., 2003). In order to investigate the role of
adenosine receptors in the mechanism of action of guanine and in-
osine, a separate group of animals was treated 15 min prior to the
treatments with an i.p. injection of the non-selective (A1 and A2A)
adenosine receptor antagonist caffeine (10 mg/kg), the selective A1
adenosine receptor antagonist DPCPX (1 mg/kg), or the selective A2A
adenosine receptor antagonist SCH58261 (0.5 mg/kg). Caffeine,
DPCPX and SCH58261 doses were adapted from elsewhere (Lara
et al., 2001; Schmidt et al., 2009a,b).
2.4. Tail-ﬂick
Nociception was assessed with a tail-ﬂick apparatus (Albrasch
Electronic Equipments, Brazil), as described in detail elsewhere
(D’Amour and Smith, 1941). A source of light was positioned above
the tail and the time that the mouse took to withdraw its tail from
the noxious stimulus was recorded. A cut-off time of 10 s was
employed in order to prevent tissue damage. At day one, the an-
imals were habituated to the tail-ﬂick apparatus with three se-
parate measures (data not shown). At day two, baseline tail-ﬂick
latency was measured for each mouse prior to treatments; animals
displaying at least two tail-ﬂick latencies of 10 s on the baseline
were excluded from the study. Immediately after the third tail-
ﬂick latency measurement, animals received i.t. treatments and
5 min thereafter were submitted to the tail-ﬂick.
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The hot-plate test was used to measure the response latencies
according to the method described by Eddy and Leimback (1953).
The hot-plate apparatus (Ugo Basile, model-DS 37, Italy) was
maintained at 5570.5 °C. Animals were placed into a glass cy-
linder of 24 cm diameter on the heated surface, and the time be-
tween placement of the animal on the hot-plate and the occur-
rence of licking hindpaws or jumping off the surface was recorded
as response latency. On day one, the animals were ﬁrst habituated
with the apparatus. On day two, mice were tested and animals
displaying baseline latencies of more than 15 s were excluded
from the study. An automatic 20 s cut-off was used to prevent
tissue damage. Each animal was tested before administration of
drugs in order to obtain the baseline. Five min after i.t. treatments,
animals were placed on the heated surface and response latency
recorded as described above.
2.6. Acetic acid-induced abdominal constriction
The abdominal constriction was induced according to Corrêa et al.
(1996) and resulted in contraction of the abdominal muscle together
with a stretching of the hind limbs in response to an i.p. injection of
acetic acid (1.6%). Five min after i.t. treatments, mice received an i.p.
injection of acetic acid. The number of abdominal constrictions fol-
lowing the irritant injectionwere counted cumulatively over a period
of 20 min. Antinociceptive activity was expressed as the reduction in
the number of abdominal constrictions.
2.7. Capsaicin-induced nociception
The method used for capsaicin-induced licking was similar to
that described by Sakurada et al., (1993). Five min after i.t. treat-
ments, 20 μl of capsaicin (1.6 μg/paw) was injected intraplantarly
(i.pl.) under the plantar skin of the right hindpaw (Hamilton mi-
crosyringe with a 26-gauge needle). Animals were observed in-
dividually for 5 min after capsaicin administration for the time
spent licking the injected paw, which was considered as indicative
of nociception.
2.8. Glutamate-induced nociception
The procedure used was similar to Beirith et al., (2002). Five
min after the i.t. treatments, 20 μl of glutamate solution (10 μmol/
paw) was injected i.pl. under the plantar skin of the right hindpaw.
The mice were observed individually for 15 min following gluta-
mate injection and the amount of time spent licking the injected
paw was considered as indicative of nociception. Considering that
the i.pl. glutamate test involves peripheral and central mechan-
isms of nociception, the i.pl. glutamate pain model was chosen for
some mechanistic studies.
2.9. Spinal algogen-induced nociception-related behaviour in mice
To test the hypothesis that excitatory amino acids or capsaicin
might be involved in the antinociception caused by guanine or
inosine, we examined the effect of both purine nucleosides on the
biting response induced by those algogens. For this purpose, mice
received guanine or inosine by i.t. route (8 μl, dose range: 200–
600 nmol) or vehicle (30 mN NaOH) 5 min before i.t. injection of
5 μl of the excitatory amino acids or capsaicin. The nociceptive
response was elicited by glutamate (an excitatory amino acid,
175 nmol/site, i.t.) (Scheidt et al., 2002), NMDA (a selective agonist
of NMDA subtype of glutamatergic ionotropic receptors, 450 pmol/
site, i.t.) (Urca and Raigorodsky, 1988), AMPA (a selective agonist of
AMPA-subtype of glutamatergic ionotropic receptors, 135 pmol/site, i.t.) (Brambilla et al., 1996), kainate (a selective agonist of
kainate subtype of glutamatergic ionotropic receptors, 110 pmol/
site, i.t.), trans-ACPD (a metabotropic glutamate receptor agonist,
50 nmol/site, i.t.) (Boxall et al., 1998), or capsaicin (TRPV1 receptor
agonist, 30 ng/site, i.t.) (Sakurada et al., 1996). A group of mice
received only vehicle (saline) by i.t. route and no signiﬁcant biting
behaviour was observed (data not shown). Immediately after i.t
injection of each nociceptive agent, mice were placed individually
in observation chambers, and the amount of time (s) the animal
spent biting itself was evaluated: glutamate (3 min); NMDA
(5 min); AMPA (1 min); kainate (4 min); trans-ACPD (15 min); or
capsaicin (6 min). A bite was deﬁned as a single head movement
directed at the ﬂanks or hind limbs, resulting in contact of the
animal’s snout with the target organ.
2.10. Hole-board test
The hole-board apparatus (Ugo Basile, Italy) consisted of grey
panels (4040 cm, 2.2 cm thick) with 16 equidistant holes 3 cm in
diameter in the ﬂoor. Photocells below the surface of the holes
measured the number of head-dips. The board was positioned
15 cm above the table and divided into nine squares of 1010 cm.
Five min after i.t. treatments, each animal was placed singly in the
centre of the board facing away from the observer and its beha-
viour recorded for 5 min. The number of head-dips, crossings
(number of squares crossed with all four paws), rearings, groom-
ings, and defecations were recorded, as well as the latency to start
locomotion (Vinadé et al., 2003).
2.11. Measurement of motor performance and general toxicity
In order to evaluate non-speciﬁc muscle relaxant or neurotoxic
effects, we evaluated the effects of i.t. guanine or inosine in the
rotarod test and on the spontaneous locomotor activity test. The
rotarod apparatus (Ugo Basile, Italy) consisted of a rotating
(18 rpm) bar (2.5 cm diameter), subdivided by discs into six
compartments, as previously described (Vinadé et al., 2003). The
method for the spontaneous locomotor activity was adapted from
Creese et al. (1976). Activity cages (452520 cm, Albarsch,
Brazil), equipped with three parallel photocells, automatically re-
cord the number of crossings. Animals were individually habi-
tuated to an activity cage for 10 min before receiving the i.t.
treatments. The animals returned to the activity cages 5 min after
i.t. treatments, and the crossings were recorded for 15 min. In
order to investigate the potential general toxicity of i.t. guanine or
inosine, mice received a single i.t. administration of vehicle, gua-
nine or inosine (up to 600 nmol) and were observed up to 72 h
thereafter. The body weight gain and number of death of animals
were recorded every 24 h, as an indication of general toxicity.
2.12. Cerebrospinal ﬂuid (CSF) sampling
Mice were treated with i.t. injection of vehicle (30 mN NaOH),
guanine or inosine (600 nmol). After 5 min, mice were anaes-
thetised with sodium thiopental (60 mg/kg, 10 ml/kg, i.p.) and
placed in a stereotaxic apparatus, where the CSF was drawn (10–
20 μl per mouse) by direct puncture of the cisterna magna with an
insulin syringe (27 gauge½ in length), with the help of a mag-
nifying glass. All samples were centrifuged at 10,000g in an Ep-
pendorf centrifuge during 5 min to obtain cell-free supernatants
and stored in separate tubes in 80 °C.
2.13. HPLC procedure
High-performance liquid chromatography (HPLC) was per-
formed with CSF cell-free supernatants aliquots for determination
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concentrations of the following purines were determined: ade-
nosine triphosphate (ATP), adenosine diphosphate (ADP), adeno-
sine monophosphate (AMP), adenosine, guanosine triphosphate
(GTP), guanosine diphosphate (GDP), guanosine monophosphate
(GMP), guanosine, inosine monophosphate (IMP), inosine, hy-
poxanthine, xanthine, and uric acid. Analyses were performed
with Shimadzu Class-VP chromatography system consisting of a
quaternary gradient pump with vacuum degassing and piston
desalting modules, Shimadzu SIL-10AF auto injector valve with
50 μl loop, and an UV detector. Separations were achieved on a
Supelco C18 250 mm4.6 mm, 5 μm particle size column. The
mobile phase ﬂowed at a rate of 1.2 ml/min and the column
temperature was 24 °C. Buffer composition remained unchanged
((A) 150 mmol/l phosphate buffer, pH 6.0, containing 150 mmol/l
potassium chloride; (B) 15% acetonitrile in buffer A). The gradient
proﬁle was modiﬁed to the following content of buffer B in the
mobile phase: 0% at 0.00 min, 2% at 0.05 min, 7% at 2.45 min, 50%
at 10.00 min, 100% at 11.00 min, and 0% at 12.40 min. Samples of
10 μl were injected into the injection valve loop. Absorbance was
read at 254 nm. CSF concentrations of purines are expressed as
mean7S.E.M. in μM.
2.14. Statistical analysis
Data are expressed as mean7standard error (S.E.M.), except
the ID50 values (i.e., the dose of guanine or inosine necessary to
reduce the nociceptive response by 50% relative to the control
value), which are reported as geometric means accompanied by
their respective 95% conﬁdence limits. The ID50 values were de-
termined by linear regression from individual experiments
(GraphPad software, USA). For tail-ﬂick and hot-plate experiments,
data are expressed as mean percent of maximum possible effect (%
MPE)7S.E.M., according to the following formula: %MPE: 100
(postdrug latencybaseline latency)/(Cutoff timebaseline la-
tency) (Calcagnetti et al., 1990). Data were submitted to Kolmo-
gorov–Smirnov test for normality evaluation. Differences were
assessed by one-way analysis of variance (ANOVA) followed by the
post-hoc Bonferroni test or Kruskal–Wallis followed by the post-
hoc Dunn test when necessary. All results with Po0.05 were
considered statistically signiﬁcant.3. Results
3.1. Effects of guanine or inosine in pain models
The results presented in Figs. 1 and 2 show that i.t. adminis-
tration of guanine (200–600 nmol) or inosine (200–600 nmol)
produces antinociception against the i.pl. glutamate – (Figs. 1A and
2A), i.pl. capsaicin – (Figs. 1B and 2B), tail-ﬂick – (Figs. 1C and 2C),
and i.p. acetic acid – (Figs. 1E and 2E) induced pain. However, only
inosine (600 nmol) produced antinociception in the hot-plate (2D)
test. Neither i.t. saline nor 30 mN NaOH affected nociception as
compared to control (sham) animals (data not shown). Mean ID50
values (95% conﬁdence limits) and maximal inhibitions for i.t.
guanine or inosine in the capsaicin, glutamate and acetic acid tests
are described in Table 1.
3.2. Effects of guanine or inosine against spinal algogen-induced
nociception
Intrathecal guanine (600 nmol – Fig. 3) signiﬁcantly inhibited
the nociceptive response induced by i.t. injection of glutamate
(Fig. 3A) or AMPA (Fig. 3B). In contrast, guanine did not produce
signiﬁcant effects against kainate (Fig. 3C), trans-ACPD (Fig. 3D),NMDA (Fig. 3E) or capsaicin (Fig. 3F) mediated biting response in
mice. Intrathecal inosine (600 nmol – Fig. 3) signiﬁcantly inhibited
the nociceptive response induced by i.t. injection of capsaicin
(Fig. 3F). In contrast, inosine had no effects against glutamate
(Fig. 3A), AMPA (Fig. 3B), kainate (Fig. 3C), trans-ACPD (Fig. 3D) or
NMDA (Fig. 3E) mediated biting response in mice.
3.3. Role of adenosine receptors in guanine- and inosine-induced
spinal antinociception
As shown in Fig. 4, i.t. guanine (600 nmol), as well as inosine
(600 nmol), produced antinociceptive effects against i.pl. gluta-
mate-induced pain, an effect prevented by pretreatment with the
non-selective adenosine receptor antagonist caffeine (10 mg/kg, i.
p., Fig. 4A). Fig. 4B shows that the selective A1 adenosine receptor
antagonist DPCPX (0.1 mg/kg, i.p.), but not the selective A2A ade-
nosine receptor antagonist SCH58261 (0.5 mg/kg, i.p.), prevented
antinociception induced by both purines in the i.pl. glutamate pain
test. Notably, adenosine receptor antagonists had no anti-
nociceptive effect per se.
3.4. Guanine- or inosine-induced general toxicity
In the hole-board test, i.t. guanine or inosine (up to 600 nmol)
did not affect latency to ﬁrst head-dip, and the number of head-
dips, crossings, rearings, groomings and defecations as compared
to control (Table 2). Intrathecal guanine or inosine did not cause
motor deﬁcits or ataxia, as evaluated by the performance in the
rotarod test and did not affect spontaneous locomotor activity as
measured by activity cages (Table 2). Intrathecal guanine or in-
osine lethal-dose is necessarily 4600 nmol, the highest dose here
used. Additionally, no signiﬁcant differences were seen in body
weight of mice treated with guanine or inosine (data not shown).
3.5. Effects of guanine or inosine on CSF purine levels
As evidenced in the Tables 3 and 4, i.t. administration of gua-
nine (up to 600 nmol) produced a signiﬁcant increase in AMP,
inosine, xanthine and uric acid CSF levels. Additionally, i.t. ad-
ministration of inosine (600 nmol) produced a signiﬁcant increase
in ATP, ADP, AMP, adenosine, inosine, hypoxanthine, xanthine and
uric acid CSF levels. Moreover, the GTP, GDP, GMP, IMP and gua-
nosine CSF levels were not affected by guanine or inosine.4. Discussion
4.1. The antinociceptive effects of guanine or inosine
The results of the present study extend previous data (Schmidt
et al., 2008; Nascimento et al., 2014) and clearly demonstrate that
guanine and inosine, following spinal administration, are anti-
nociceptive in several thermal and chemical pain models in mice.
We also demonstrate that these antinociceptive effects may in-
volve adenosine receptors. However, some additional mechanisms
might be involved into those effects, since inosine inhibited biting
behaviour induced by i.t. administration of capsaicin, while gua-
nine prevented biting behaviour induced by i.t. glutamate and
AMPA.
Adenine-based purines have been considered important targets
for the development of new drugs for pain management, since the
nucleoside adenosine and its analogues are antinociceptive fol-
lowing both systemic and central administration (Sawynok and
Liu, 2003). Considering that adenine- and guanine-based purines
closely interact in modulating several CNS functions (Dobolyi et al.,
2000), we have recently investigated the antinociceptive effects of
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Fig. 1. Effects of i.t. administration of vehicle (30 mN NaOH), morphine (Mor – 10 nmol), or guanine (200, 400 or 600 nmol) in the i.pl. glutamate (A), i.pl. capsaicin (B), tail-
ﬂick (C), hot-plate (D), and i.p. acetic acid (E) tests in mice. (A, B, and E) Columns represent mean time spent in licking the injected hindpaw, and vertical bars represent S.E.
M. (C and D) Columns represent mean percent of maximum possible effect (%MPE), and vertical bars represent S.E.M. N¼8–12. nPo0.05, nnPo0.01 and nnnPo0.001
compared to vehicle (Panel A: F¼4.12; Panel B: F¼8.0; Panel C: F¼5.46; Panel E: F¼3.98), one-way ANOVA followed by Bonferroni test or Kruskal–Wallis followed by the
Dunn test.
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and guanosine produced consistent antinociceptive effects in
several pain models. We also demonstrated that GMP-induced
antinociception was prevented by the 5′-nucleotidase inhibitor
AOPCP, suggesting that its effects result from conversion to gua-
nosine or subsequent metabolites. Additionally, we have demon-
strated that spinal, intraperitoneal and oral administration of
guanosine produce antinociception in several pain models in mice
(Schmidt et al., 2008).4.2. Guanine-induced antinociception and the purinergic system
In the CNS, extracellular guanine-based purines are primarily
released from glial cells, most likely as nucleotides that are me-
tabolised by ecto-nucleotidases to extracellular guanosine (Rath-
bone et al., 1999). Guanosine stimulates mitosis, synthesis of
trophic factors, and cell differentiation, is neuroprotective, and
reduces apoptosis due to several stimuli (Rathbone et al., 2008).
Additionally, there is evidence indicating that extracellular gua-
nine might be related to neuroprotective effects caused by the
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compared to vehicle (Panel A: F¼5.31; Panel B: F¼13.47; Panel C: F¼3.09; Panel D: F¼10.7; Panel E: F¼5.01), one-way ANOVA followed by Bonferroni test or Kruskal–Wallis
followed by the Dunn test.
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Souza, 2010) and previous data indicated that guanosine and
guanine enter the CNS, despite active purine metabolism in the
peripheral tissues (Moriwaki et al., 1999; Jiang et al., 2007, 2008).
Therefore, antinociceptive effects of guanine-based purines
could be regulated by conversion of guanosine to guanine by a
membrane located purine nucleoside phosphorylase (ecto-PNP)and by conversion of guanine to xanthine by guanine deaminase
(Fig. 5).
In the present study, the spinal administration of guanine
caused a signiﬁcant increase in CSF levels of oxypurines (xanthine
and uric acid), which probably indicates an in vivo degradation. We
have previously demonstrated that the spinal administration of
guanosine also caused a signiﬁcant increase in the CSF levels of
Table 1
Mean ID50 values (95% conﬁdence limits) and maximal inhibitions for i.t. guanine
or inosine against capsaicin, glutamate, and acetic acid pain tests.
Pain Model Guanine (i.t.) Inosine (i.t.)
Mean ID50 (nmol – 95% conﬁdence limits):
Capsaicin 84 (31–230) 88 (29–267)
Glutamate 107 (83–137) 85 (64–112)
Acetic acid 48 (13–173) 42 (21–83)
Maximal Inhibitions (%):
Capsaicin 58714 52712
Glutamate 48715 58713
Acetic acid 56710 7276
Effects of i.t. guanine or inosine in pain models (Mean ID50 values795% conﬁdence
limits and maximal inhibitions). Vehicle (30 mN NaOH), guanine or inosine was i.t.
administered 5 min prior to pain tests. Data are expressed as geometric means
accompanied by their respective 95% conﬁdence limits. Differences were assessed
by linear regression from individual experiments.
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guanosine administration caused similar neurochemical and be-
havioural effects, these ﬁndings might indicate that degradation of
guanosine or guanine into the ﬁnal products xanthine and uric
acid could play a role in their antinociceptive effects (Fig. 5).
However, previous experiments showed that spinal administration
of xanthine (up to 600 nmol) did not affect nociception in several
pain models in mice (data not published). Unfortunately, our HPLC
methodology was not accurate to measure CSF guanine levels. In
fact, we observed a small increase in inosine levels following
guanine administration, which may actually represent guanine
detection. However, more accurate methodology to isolate and
measure guanine should be applied in future research.
Adenine- and guanine-based purines share some metabolism
steps (i.e., nucleoside transporters and ecto-nucleotidases), and,
consequently, may respond similarly in certain conditions (Cic-
carelli et al., 2001). Previous studies have suggested involvement
of the adenosinergic system in effects of guanosine, since guano-
sine stimulates the release of adenosine in cultured astrocyte, and
both are released under excitotoxic conditions (Ciccarelli et al.,
2001). Previous ﬁndings from our group demonstrated that a
pretreatment with non-selective and selective A1/A2A receptor
antagonists signiﬁcantly affected systemic guanosine-induced an-
tinociception (Schmidt et al., 2010a). Similarly, the present results
indicate that guanine-induced antinociception was signiﬁcantly
affected by the administration of non-selective and selective A1
receptor antagonists. Therefore, at least for guanine-induced an-
tinociception, adenosine receptors, especially A1 receptors, seem
to be relevant.
4.3. Inosine-induced antinociception and the purinergic system
Inosine is an endogenous nucleoside produced through the
breakdown of ATP and adenosine via enzymatic cascades includ-
ing ATPase and adenosine deaminase enzymes (Sawynok and Liu,
2003). Previous studies indicated that its central and systemic
administration display antinociceptive and anti-inﬂammatory ef-
fects in animals. Pharmacological and biochemical evidence have
suggested that these ﬁndings might involve activation of adeno-
sine receptors, the protein kinase C pathway, pertussis toxin-sen-
sitive G-proteins, Kþ channels and voltage-gated Caþ2 channels
(Nascimento et al., 2010; da Rocha Lapa et al., 2012, 2013; Macedo-
Junior et al., 2013). The present study indicates that spinal ad-
ministration of inosine produced marked and dose-dependent
antinociception when assessed in a variety of pain models.More recently, Nascimento et al. (2014) further characterized
that the activation of A1 adenosine receptors at central sites is
involved in the inosine-induced antinociception. Interestingly,
these ﬁndings indicate that inosine might be a putative en-
dogenous ligand of A1 receptors, since it binds to A1 receptors with
an afﬁnity similar to adenosine (Nascimento et al., 2014). In the
present study, the involvement of A1 adenosine receptors in the
antinociceptive action of inosine is clearly demonstrated. Our re-
sults show that pretreatment of animals with DPCPX, but not with
SCH58261, signiﬁcantly prevented the antinociception caused by
inosine in the i.pl. glutamate test. Notably, Nascimento et al. (2010)
have shown that the antagonism of both A1 and A2A adenosine
receptors are involved in the antinociception induced by inosine.
Although the role of A1 adenosine receptors in pain mechanisms is
relatively well established, the role of the receptor A2A in noci-
ception remains controversial. Previous studies have demon-
strated conﬂicting results, showing that A2A agonists may produce
both antinociceptive and pronociceptive actions in animals (Doak
and Sawynok, 1995). This variation of results may be related to the
site of agonist/antagonist administration, receptor selectivity and
tissue distribution, dosage regimen, or even could depend on the
intensity and modality of the stimulus. In the present study, we
demonstrated that SCH58261 did not affect the antinociceptive
action of inosine, differing from a previous study (Nascimento
et al., 2010).
As stated for guanine metabolism, the spinal administration of
inosine caused a signiﬁcant increase in CSF levels of oxypurines,
mainly hypoxanthine, which probably indicates an in vivo de-
gradation. Inosine can be converted to hypoxanthine by ecto-PNP
and in vitro studies have indicated that the protective effect of in-
osine depends on the conversion inosine to hypoxanthine by ecto-
PNP (Fig. 5). However, previous data indicated that hypoxanthine
did not play a role in the inosine-induced neuroprotection against
stroke in rats and against oxygen-glucose deprivation in astrocyte
cultures (Shen et al., 2005). Of note, spinal administration of hy-
poxanthine (up to 600 nmol) did not affect nociception in several
pain models in mice (data not published). Because hypoxanthine is
the main substrate for hypoxanthine-guanine phosphoribosyl
transferase (HGPRT) to form inosine 5-monophosphate (IMP) and
then ATP, the lack of efﬁcacy of hypoxanthine indicates that inosine-
mediated antinociception is probably not mediated by the pro-
duction of active metabolite hypoxanthine or ATP.
4.4. Additional insights into the mechanism of action of extracellular
guanine and inosine
Glutamate and its receptors play crucial roles in pain trans-
mission and the modulation of glutamate receptors may have
therapeutic potential for several categories of pain (Millan, 1999).
Although the overall effects of the extracellular guanine-
and adenine-based purines may be related to attenuating gluta-
matergic overstimulation, their precise mechanism of action re-
mains unclear. In this study, spinal administration of guanine
produced a signiﬁcant inhibition of the biting behaviour induced
by i.t. injection of glutamate and AMPA but not against
NMDA, kainate and trans-ACPD. Thus, we suggest that the anti-
nociceptive effect caused by guanine, similar to other guanine-
based purines, may involve an interaction with the glutamatergic
system and its receptors, and/or with their signal transduction
mechanisms.
In vitro, guanine-based purines have been shown to prevent
ischaemic injury (Frizzo et al., 2002) and NMDA-induced ex-
citotoxicity (Ciccarelli et al., 2001). In vivo, the guanine-based
purines are neuroprotective against stroke and spinal cord injury
(Jiang et al., 2003; 2007; 2008; Chang et al., 2008) and prevent
seizures and toxicity induced by drugs that overstimulate the
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we demonstrated that central and systemic administration
of the nucleoside guanosine prevent the i.pl. capsaicin-induced
changes in cortical and spinal cord glutamate uptake (Schmidt
et al., 2008). These results together with the evidence that the
guanine-based purines may alter the glutamate uptake in vitro
(Frizzo et al., 2002) suggest that the antinociceptive effects of the
guanine-based purines, including guanosine and guanine, might
involve the modulation of the glutamate removal from the sy-
naptic cleft, consequently downplaying glutamatergic receptors
activation.Inosine elicits protection and regeneration during various CNS
injuries largely associated to glutamatergic excitotoxicity. Inosine,
similarly to adenosine, has been shown to be neuroprotective
against stroke and ischaemia models (Shen et al., 2005). Inter-
estingly, NMDA-induced excitotoxicity stimulate the production
and release of both inosine and adenosine (Zamzow et al., 2009),
which could be related to an endogenous neuroprotective path-
way. However, in the present study, inosine did not affect biting
behaviour induced by i.t. administration of glutamate agonists,
indicating that glutamate receptors might be not involved in the
antinociceptive effects of inosine. Conversely, inosine reduced
Fig. 4. Effects of caffeine (10 mg/kg, i.p., panel A), DPCPX (1 mg/kg, i.p., panel B) or SCH58261 (0.5 mg/kg, i.p., panel B) 15 min before i.t. vehicle (30 mN NaOH), guanine or
inosine (600 nmol) in the i.pl. glutamate test in mice. Columns represent mean time spent in licking the injected hindpaw, and vertical bars represent S.E.M. N¼8–12.
nnnPo0.001 compared to vehicle (Panel A: F¼3.65 – guanine and F¼6.6 – inosine; Panel B: F¼5.33 – guanine and F¼4.05 – inosine), one-way ANOVA followed by
Bonferroni test.
Table 2
Effects of i.t. vehicle (30 mN NaOH), guanine or inosine (600 nmol) on the hole-
board, rotarod and spontaneous locomotion in mice.
Treatment 30 mN NaOH Guanine Inosine
Latency to head-dip (s) 4.7 (1.2) 4.8 (1.4) 5.1 (1.2)
Head-dips (n) 82.9 (5.5) 86.7 (7.3) 81.9 (6.3)
Squares crossed (n) 45.3 (4.9) 52.3 (7.1) 47.2 (10.3)
Rearings (n) 1.6 (0.8) 1.3 (0.8) 1.5 (0.6)
Groomings (n) 1.6 (0.5) 1.3 (0.4) 1.1 (0.4)
Faecal boli (n) 0.9 (0.3) 1.4 (0.5) 1.5 (0.5)
Latency to fall (s) 59.3 (0.6) 59.6 (0.5) 56.8 (2.3)
Crossings (n) 146 (22) 135 (25) 160 (25)
Vehicle (30 mN NaOH), guanine or inosine (600 nmol) were i.t. administered 5 min
prior to the behaviour measurements: latency to the ﬁrst head-dip; head-dips;
squares crossed; rearings; groomings; faecal boli (hole board); latency to fall (ro-
tarod); number of crossings (spontaneous locomotion). N¼8. Data are mean7S.E.
M. One-way ANOVA.
Table 3
Effects of i.t. vehicle (30 mN NaOH) or guanine (200, 400 or 600 nmol) on CSF
purines concentration.
Treatment 30 mN NaOH Guanine (nmol, i.t.)
200 400 600
CSF purine concentration (μM):
ATP 0.19 (0.03) 0.23 (0.04) 0.19 (0.03) 0.41 (0.13)
ADP 0.64 (0.08) 1.34 (0.24) 1.00 (0.17) 1.18 (0.16)
AMP 0.85 (0.15) 0.87 (0.10) 0.84 (0.06) 1.49 (0.16)a
Adenosine 0.53 (0.07) 0.30 (0.03) 0.54 (0.14) 0.44 (0.09)
GTP 0.87 (0.06) 0.64 (0.06) 0.67 (0.05) 0.62 (0.09)
GDP 0.54 (0.05) 0.69 (0.11) 0.38 (0.07) 0.46 (0.08)
GMP 1.96 (0.48) 1.85 (0.13) 1.62 (0.53) 1.07 (0.28)
Guanosine 0.57 (0.12) 0.72 (0.18) 0.89 (0.13) 0.96 (0.08)
IMP 1.72 (0.19) 1.07 (0.39) 1.15 (0.46) 1.57 (0.46)
Inosine 2.18 (0.30) 5.12 (1.7) 11.43 (2.18)a 13.60 (6.19)b
Hypoxanthine 3.90 (0.58) 5.47 (0.85) 6.48 (1.52) 6.40 (1.28)
Xanthine 3.48 (0.58) 4.75 (0.47) 7.20 (0.52)c 8.38 (0.75)c
Uric acid 3.83 (0.57) 6.85 (0.35)b 6.57 (0.73)a 5.54 (0.64)a
Effects of i.t. vehicle (30 mN NaOH) or guanine (200, 400 or 600 nmol) on CSF
purines concentration. N¼8. Data are mean7(S.E.M.).
a Po0.05,
b Po0.01, and
c Po0.001 as compared to vehicle, one-way ANOVA followed by the Bonferroni
test.
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direct or indirect effect on TRPV1 receptors at the spinal cord.
4.5. Spinal guanine or inosine administration and general toxicity
Adenine-based purines produce important side effects such as
impaired motor function and sedation (Sawynok and Liu, 2003).
Our present results indicate that neither guanine nor inosine in-
duces any obvious behavioural disturbances (hole-board) or alters
coordination (rotarod) or locomotion (activity cages). The minor
toxic potential of both purines was also evidenced by the low in-
dex of mortality (none at doses up to 600 nmol), and lack of al-
terations in weight body gain or general behaviour up to 72 h after
spinal guanine or inosine administration. These results are con-
sistent with previous data regarding other guanine- and adenine-
based purines (Vinadé et al., 2003; Schmidt et al., 2008).
4.6. Conclusions and perspectives
In summary, this study provides additional data about the
mechanisms involved in the antinociceptive effects of purinederivatives in mice. Because both guanine and inosine are en-
dogenous compounds and apparently well tolerated, they could
eventually be developed as useful drugs for managing pain. This
study also provides new evidence on the role of extracellular
guanine and inosine in the CNS, and indicates that both purines
may present, at least partially, a similar mechanism of action,
producing antinociceptive effects mediated by the adenosinergic
system. Additionally, our ﬁndings indicate that the antinociceptive
effects of guanine and inosine may involve glutamate receptors
(AMPA receptors) and TRPV1 receptors, respectively. These results
do not exclude the involvement of other neurochemical para-
meters rather than glutamatergic and adenosinergic system in the
guanine and inosine antinociceptive effects. On going experiments
on the antinociceptive effects of guanine- and adenine-based
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Table 4
Effects of i.t. vehicle (30 mN NaOH) or inosine (200, 400 or 600 nmol) on CSF purines concentration.
Treatment 30 mN NaOH Inosine (nmol, i.t.)
200 400 600
CSF purine concentration (μM):
ATP 0.19 (0.03) 0.48 (0.06)a 0.57 (0.11)b 0.62 (0.22)a
ADP 0.64 (0.08) 1.73 (0.31)a 1.58 (0.13)a 1.37 (0.27)
AMP 0.85 (0.15) 2.36 (0.27)a 2.45 (0.77)a 1.90 (0.10)
Adenosine 0.53 (0.07) 0.92 (0.09)a 0.60 (0.13) 0.88 (0.07)a
GTP 0.87 (0.06) 0.79 (0.06) 0.78 (0.08) 0.87 (0.04)
GDP 0.54 (0.05) 1.07 (0.30) 0.46 (0.10) 0.87 (0.07)
GMP 1.96 (0.48) 2.19 (0.66) 2.05 (0.48) 1.50 (0.62)
Guanosine 0.57 (0.12) 0.81 (0.15) 2.03 (0.48) 1.95 (0.78)
IMP 1.72 (0.19) 2.07 (0.49) 1.11 (0.29) 2.78 (0.36)
Inosine 2.18 (0.30) 28.06 (3.12)a 251.9 (21.5)c 201.4 (37.4)c
Hypoxanthine 3.90 (0.58) 18.47 (4.09)a 50.03 (9.74)c 49.91 (8.99)c
Xanthine 3.48 (0.58) 5.53 (0.81) 6.08 (0.64) 9.82 (2.09)c
Uric acid 3.83 (0.57) 7.33 (0.80)a 6.53 (0.54)a 9.29 (1.64)c
Table 4: Effects of i.t. vehicle (30 mN NaOH) or inosine (200, 400 or 600 nmol) on CSF purines concentration. N¼8. Data are mean7(S.E.M.).
a Po0.05,
b Po0.01, and
c Po0.001 as compared to vehicle, one-way ANOVA followed by the Bonferroni test.
E.D. de Oliveira et al. / European Journal of Pharmacology 772 (2016) 71–8280purines and their metabolites against chronic pain models, and the
mechanisms underlying these effects, shall provide additional data
on the potential of some endogenous purines as a new analgesic
strategy. Better comprehension of their biological effects, theirmetabolism and the mechanisms through which their effects are
mediated may prove useful not only in understanding the phy-
siological and pathological processes in the CNS, but also in tar-
geting interventions for several pathological conditions.
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